ABMD reports preliminary results

Abiomed announced preliminary Q3 results after the market close today.


FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year

Preliminary unaudited U.S. revenue from Impella® products grew 45% to approximately $75.0 million from $51.9 million in the prior fiscal year.

For the third quarter of fiscal 2016, U.S. patient usage grew 45% in comparison with same period of fiscal 2015.



only up 1.76% after hours (per Yahoo). interesting. Maybe we have a good market sell off again tomorrow and it dips a bit for us. Still long.